Why the study?
Does landiolol improve acute rate control in patients with atrial fibrillation and cardiac dysfunction?
Does landiolol improve acute rate control in patients with atrial fibrillation and cardiac dysfunction?
Landiolol is an ultra-short acting beta-blocker that represents a potential option for acute rate control in patients with atrial fibrillation and concurrent heart failure.
Landiolol's European availability may broaden acute AF rate-control choices in HF; leaves open need for local RCTs before practice adoption.
Atrial fibrillation (AFib) is frequently associated with heart failure. Guidelines for AFib management have been recently updated and include an algorithm for acute heart rate control based on left ventricular ejection fraction and haemodynamics. Landiolol is an injectable ultra-short beta-blocker with very high beta-1 selectivity, listed in Japanese Guidelines for AFib management as potential option for rate control of patient with heart failure. Landiolol is now available in Europe with indication of controlling heart rate in AFib and supraventricular tachycardia. This review discusses existing clinical data in Japan and perspectives of landiolol use for acute rate control of AFib patients with cardiac dysfunction.
No takes yet. Share an insight, caveat, or question.
Haehling et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: